D-Pharm Completes Enrollment for the Phase IIb trial of DP-b99 in Acute Stroke Patients

D-Pharm Completes Enrollment for the Phase IIb trial of DP-b99 in Acute Stroke Patients: "D-Pharm announced today completion of enrollment in its Phase IIb clinical trial of DP-b99. DP-b99 is a unique neuroprotective drug that addresses the array of damaging processes occurring in the brains of stroke patients. The Phase IIb trial results are expected to be available towards the end of 2006 following completion of the 3 month follow-up period."